AI assistant
Sending…
Insight Molecular Diagnostics Inc. — Director's Dealing 2023
Aug 17, 2023
34238_dirs_2023-08-17_de95d9de-b000-4fc9-a997-d709d94e2705.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2023-08-15
Reporting Person: Riggs Josh (Director, CEO and President)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-08-15 | Option to Purchase Common Stock | $3.34 | A | 40000 | Acquired | 2033-08-15 | Common Stock (40000) | Direct |
Footnotes
F1: The options will vest and thereby be exercisable on December 31, 2025, based on achievement of certain specified targets with respect to the 30-day volume-weighted average price of Company's common stock, measured as of the end of each full calendar month up through December 31, 2025, subject to continuous services through December 31, 2025.
More from Insight Molecular Diagnostics Inc.
Annual Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Regulatory Filings
2026
Feb 26
Capital/Financing Update
2026
Feb 12
Director's Dealing
2026
Feb 12
Major Shareholding Notification
2026
Feb 12
Investor Presentation
2026
Feb 11
Capital/Financing Update
2026
Feb 11
Director's Dealing
2025
Nov 13
Interim / Quarterly Report
2025
Nov 10